PILA PHARMA AB (publ) (FN STO: PILA) has announced its participation in the upcoming Aktiespararna's 'Store Aktiedagarna' event. This highly anticipated presentation is scheduled for tomorrow, Wednesday, June 12, 2024, at 08:00 CET. The event will take place physically in Stockholm, Sweden, and will also be available via livestream. Interested parties and investors are encouraged to follow the event, ask questions, and sign up through the provided link: https://www.aktiespararna.se/aktiviteter/aktiedagarna-i-stockholm-42149.

At the event, CEO Gustav H. Gram will delve into PILA PHARMA's latest advancements, focusing on their innovative oral treatment, which holds promise for treating diabetes and potentially associated metabolic disorders. The presentation will be conducted in English and will include a Q&A session, allowing participants to engage directly with the company's leadership.

PILA PHARMA, based in Malmö, Sweden, is a biotech company dedicated to developing TRPV1 antagonists as a novel treatment for type 2 diabetes and other diseases with an inflammatory background. The company owns a TRPV1 asset, including the development candidate XEN-D0501, and holds use-patents for TRPV1 antagonists in treating obesity and diabetes. PILA PHARMA has completed two phase 2a clinical trials demonstrating the safety and efficacy of XEN-D0501 in type 2 diabetic patients, with plans to progress into longer clinical trials.

Diabetes, particularly type 2 diabetes, is a global pandemic affecting over 537 million people worldwide. Despite recent therapeutic advances, there remains a significant unmet need for effective, safe, and accessible treatments. Obesity, a major risk factor for type 2 diabetes, further complicates the landscape, leading to a range of comorbidities and reduced quality of life.

PILA PHARMA's innovative approach with TRPV1 antagonists, specifically XEN-D0501, offers a promising avenue for addressing these challenges. The company's recent financial achievements have enabled the preparation of a phase 2a dose-escalation study aimed at identifying the maximal tolerable dose of XEN-D0501 in overweight or obese individuals with type 2 diabetes. This study will also explore potential reductions in HbA1c, body weight, and ANP, a cardiovascular disease marker.

In addition to diabetes, PILA PHARMA is exploring the use of XEN-D0501 for treating erythromelalgia, a rare and debilitating disease characterized by neurogenic inflammation and severe pain. The company is also investigating the potential of XEN-D0501 in addressing abdominal aorta aneurism growth, a cardiovascular condition with limited treatment options.

Given PILA PHARMA's innovative pipeline, strong clinical trial results, and strategic focus on addressing significant unmet medical needs, the company's future appears promising. Investors should closely monitor the outcomes of the upcoming presentation and the progress of ongoing and future clinical trials.

For more information, contact CEO Gustav H. Gram at ghg@pilapharma.com. Stay updated on news and events by visiting the company's website: https://www.pilapharma.com/.